Brain MRI identifies dementia patients who have vascular impairment rather than Alzheimer’s disease

Researchers at the University of Nottingham in England have shown that brain MRI can be used to differentiate vascular cognitive disorder from Alzheimer’s and other forms of dementia.

Dorothee Auer, MD, PhD, and colleagues used such MR imaging, along with cognitive performance tests, to assess 108 patients presenting symptoms of carotid artery disease (CAD).

Of these, 53 were found to be cognitively impaired, and the researchers’ analysis linked lesions in white-matter brain tracts with poor cognitive performance.

CAD often leads to vascular cognitive impairment in the wake of strokes and transient ischemic attacks.

“Subcortical white matter ischemic lesion locations and severity of ultrastructural tract damage contribute to cognitive impairment in symptomatic CAD,” the authors write, “which suggests that subcortical disconnection within large-scale cognitive neural networks is a key mechanism of vascular cognitive disorder.”

Stated another way, the results of the study suggest that vascular cognitive disorder is caused by a sort of communication breakdown within cognitive neural networks.

In a press release from RSNA, which published the study online Sept. 6 in Radiology, Auer says the team used standard clinical brain MRI.

“Our findings mean that a simple MRI test might improve the diagnostic work-up of people with suspected vascular cognitive disorder,” she adds, “and holds further promise to track progression of the disorder.”

RSNA points out that, while the study did not identify a biomarker that could predict and track vascular cognitive disorder on imaging exams, the MRI-aided peek into the brain’s signal-carrying white matter represent a noteworthy advance.

Click here to read the release. 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.